What is the primary mechanism of action of COX-2 inhibitors?
Master all 26 flashcards
Review newer anti-inflammatory medications, including COX-2 inhibitors and biologics, with their mechanisms and clinical roles.
Mastering this deck enables healthcare professionals to understand the latest anti-inflammatory options, choose appropriate agents based on patient-specific factors, and anticipate potential benefits and risks, thereby optimizing inflammatory disease management.
ℹ️ Educational Use Only: This flashcard deck is created by usersof our platform for their educational and study purposes. The content is not intended as medical advice, diagnosis, or treatment guidance. Always consult qualified healthcare professionals for medical decisions and verify information with authoritative medical sources.
Showing 20 of 26 cardsSample view
| # | Front | Back | Hint |
|---|---|---|---|
| 1 | What is the primary mechanism of action of COX-2 inhibitors? | COX-2 inhibitors selectively inhibit the cyclooxygenase-2 enzyme, reducing prostaglandin synthesis involved in inflammation and pain, while sparing COX-1 activity to minimize gastrointestinal side effects. | Think 'selective COX-2' as 'COX-2 targeted, GI protected'. |
| 2 | Name two clinically used COX-2 inhibitors. | Celecoxib and Etoricoxib. | Celecoxib is the most common; Etoricoxib is another option. |
| 3 | How do biologic anti-inflammatory agents differ from NSAIDs? | Biologics are targeted therapies, typically monoclonal antibodies or receptor antagonists, designed to block specific cytokines or cellular pathways involved in inflammation, whereas NSAIDs inhibit cyclooxygenase enzymes broadly. | Biologics = targeted, NSAIDs = enzyme inhibitors. |
| 4 | Give an example of a biologic used in rheumatoid arthritis. | Adalimumab, a monoclonal antibody against TNF-alpha. | Think 'ADALImumab' for TNF blockade. |
| 5 | What are the main clinical advantages of COX-2 inhibitors over traditional NSAIDs? | They provide anti-inflammatory and analgesic effects with a lower risk of gastrointestinal ulceration and bleeding. | COX-2 inhibitors = GI safety profile. |
| 6 | Name a significant adverse effect associated with long-term COX-2 inhibitor use. | Increased risk of cardiovascular events, such as myocardial infarction and stroke. | Remember 'cardio caution' with COX-2s. |
| 7 | What is the mechanism by which biologics reduce inflammation in autoimmune diseases? | Biologics block specific cytokines (e.g., TNF-alpha, IL-6) or immune cell interactions, thereby reducing the inflammatory response. | Targeted cytokine blockade. |
| 8 | Which biologic agent targets IL-6 and is used in rheumatoid arthritis? | Tocilizumab. | Think 'Toci' for IL-6. |
| 9 | What is a major limitation of biologic anti-inflammatory therapies? | High cost, risk of infections, and potential for immunogenicity leading to reduced efficacy. | Biologics = costly and immunologically active. |
| 10 | Which patient population should be monitored closely when given biologics? | Patients with a history of recurrent infections, immunosuppressed individuals, and those with latent tuberculosis. | Monitor for infection risk. |
| 11 | What is the role of Janus kinase (JAK) inhibitors in anti-inflammatory therapy? | JAK inhibitors block intracellular signaling pathways used by cytokine receptors, thus reducing inflammation; they are oral agents used in rheumatoid arthritis. | JAK inhibitors = intracellular cytokine signaling blockade. |
| 12 | Name an example of a JAK inhibitor used clinically. | Tofacitinib. | Tofa = Tofacitinib. |
| 13 | How do selective JAK inhibitors differ from broader immunosuppressants? | They target specific JAK enzymes involved in cytokine signaling, providing more precise immunomodulation with potentially fewer side effects. | Selective JAKi = precision immunotherapy. |
| 14 | What are the main clinical indications for COX-2 inhibitors? | Osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea, especially in patients at risk for GI bleeding. | Use where GI safety is a priority. |
| 15 | What is the mechanism by which biologics such as rituximab exert their anti-inflammatory effects? | Rituximab targets CD20 on B cells, leading to B cell depletion and reduced autoantibody production. | B cell targeting = Rituximab. |
| 16 | Which adverse effect is most associated with B cell-depleting biologics? | Increased risk of infections, particularly reactivation of hepatitis B or herpes zoster. | Monitor for infections. |
| 17 | Explain why selective COX-2 inhibitors may pose a cardiovascular risk. | Inhibition of COX-2 reduces prostacyclin production, which impairs vasodilation and platelet inhibition, tipping the balance toward thrombosis. | Balance prostacyclin and thromboxane effects. |
| 18 | What is the significance of the 'Chinese hamster ovary (CHO) cell expression system' in biologic drug production? | It allows large-scale, consistent production of recombinant monoclonal antibodies used as biologics. | CHO cells = biologic factory. |
| 19 | Name a biologic agent used in inflammatory bowel disease. | Infliximab, an anti-TNF-alpha monoclonal antibody. | Infliximab for IBD. |
| 20 | What is a key consideration when switching between different biologic agents? | Potential for immune reactions and loss of efficacy; washout periods or monitoring for adverse effects may be necessary. | Switching biologics requires caution. |
Note: This preview shows only the first 20 cards. The complete deck contains 26 total cards. Start studying to access all flashcards.
Master all 26 flashcards
Explore other decks you might find helpful